Vesicle shrinkage in hydrous phonolitic melt during cooling

The ascent of hydrous magma prior to volcanic eruptions is largely driven by the formation of H2O vesicles and their subsequent growth upon further decompression. Porosity controls buoyancy as well as vesicle coalescence and percolation, and is important when identifying the differences between equilibrium or disequilibrium degassing from textural analysis of eruptive products. Decompression experiments are routinely used to simulate magma ascent. Samples exposed to high temperature (T) and pressure (P) are decompressed and rapidly cooled to ambient T for analysis. During cooling, fluid vesicles may shrink due to decrease of the molar volume of H2O and by resorption of H2O back into the melt driven by solubility increase with decreasing T at P < 300 MPa. Here, we quantify the extent to which vesicles shrink during cooling, using a series of decompression experiments with hydrous phonolitic melt (5.3–3.3 wt% H2O, T between 1323 and 1373 K, decompressed from 200 to 110–20 MPa). Most samples degassed at near-equilibrium conditions during decompression. However, the porosities of quenched samples are significantly lower than expected equilibrium porosities prior to cooling. At a cooling rate of 44 K·s−1, the fictive temperature Tf, where vesicle shrinkage stops, is up to 200 K above the glass transition temperature (Tg), Furthermore, decreasing cooling rate enhances vesicles shrinkage. We assess the implications of these findings on previous experimental degassing studies using phonolitic melt, and highlight the importance of correctly interpreting experimental porosity data, before any comparison to natural volcanic ejecta can be attempted

Very Low Temperature Tunnelling Spectroscopy in the heavy fermion superconductor PrOs4_4Sb12_{12}

We present scanning tunnelling spectroscopy measurements on the heavy fermion superconductor PrOs$_4$Sb$_{12}$. Our results show that the superconducting gap opens over a large part of the Fermi surface. The deviations from isotropic BCS s-wave behavior are discussed in terms of a finite distribution of values of the superconducting gap.Comment: 4 pages, 4 figure

SN 2015bh: NGC 2770’s 4th supernova or a luminous blue variable on its way to a Wolf-Rayet star?

Very massive stars in the final phases of their lives often show unpredictable outbursts that can mimic supernovae, so-called, “SN impostors”, but the distinction is not always straightforward. Here we present observations of a luminous blue variable (LBV) in NGC 2770 in outburst over more than 20 yr that experienced a possible terminal explosion as type IIn SN in 2015, named SN 2015bh. This possible SN (or “main event”) had a precursor peaking ~40 days before maximum. The total energy release of the main event is ~1.8 × 1049 erg, consistent with a <0.5 M⊙ shell plunging into a dense CSM. The emission lines show a single narrow P Cygni profile during the LBV phase and a double P Cygni profile post maximum suggesting an association of the second component with the possible SN. Since 1994 the star has been redder than an LBV in an S-Dor-like outburst. SN 2015bh lies within a spiral arm of NGC 2770 next to several small star-forming regions with a metallicity of ~0.5 solar and a stellar population age of 7–10 Myr. SN 2015bh shares many similarities with SN 2009ip and may form a new class of objects that exhibit outbursts a few decades prior to a “hyper eruption” or final core-collapse. If the star survives this event it is undoubtedly altered, and we suggest that these “zombie stars” may evolve from an LBV to a Wolf-Rayet star over the timescale of only a few years. The final fate of these stars can only be determined with observations a decade or more after the SN-like event

Vasorelaxant effect of a phenylethylamine analogue based on schwarzinicine A an alkaloid isolated from the leaves of Ficus schwarzii

N-Phenethyl-1-phenyl-pentan-3-amine (1) is a new compound synthesised as a simplified analogue of schwarzinicine A (2), a natural compound extracted from Ficus schwarzii. Compound 1 differs from compound 2 due to its structural simplification, featuring two phenyl rings without methoxy substitution, as opposed to compound 2, which possesses three 3,4-dimethoxy aromatic rings. Our previous research findings highlighted the calcium-inhibitory effects of compound 2, but the mechanism of action for compound 1 remains unexplored, serving as the primary focus of this study. Building upon our earlier research, this study aimed to elucidate compound 1's calcium-modulating potential by using rat-isolated aortae in an organ bath set-up and HEK cells expressing hTRPC channels with the fluorometric assay to measure calcium influx. Compound 1 elicited a vasorelaxation response (Emax 111.4%) similar to its parent compound 2 (Emax 123.1%), and inhibited hTRPC3-, hTRPC4-, hTRPC5-, and hTRPC6-mediated calcium influx into HEK cells with IC50 values of 6, 2, 2, 5 µM, respectively. Compound 1 has a similar pharmacological profile as its parent compound 2, whereby it exerts a vasorelaxant effect by attenuating calcium influx and inhibits multiple TRPC channels

Optimizing real time fMRI neurofeedback for therapeutic discovery and development

While reducing the burden of brain disorders remains a top priority of organizations like the World Health Organization and National Institutes of Health, the development of novel, safe and effective treatments for brain disorders has been slow. In this paper, we describe the state of the science for an emerging technology, real time functional magnetic resonance imaging (rtfMRI) neurofeedback, in clinical neurotherapeutics. We review the scientific potential of rtfMRI and outline research strategies to optimize the development and application of rtfMRI neurofeedback as a next generation therapeutic tool. We propose that rtfMRI can be used to address a broad range of clinical problems by improving our understanding of brain–behavior relationships in order to develop more specific and effective interventions for individuals with brain disorders. We focus on the use of rtfMRI neurofeedback as a clinical neurotherapeutic tool to drive plasticity in brain function, cognition, and behavior. Our overall goal is for rtfMRI to advance personalized assessment and intervention approaches to enhance resilience and reduce morbidity by correcting maladaptive patterns of brain function in those with brain disorders

Brain function and clinical characterization in the Boston adolescent neuroimaging of depression and anxiety study

We present a Human Connectome Project study tailored toward adolescent anxiety and depression. This study is one of the first studies of the Connectomes Related to Human Diseases initiative and is collecting structural, functional, and diffusion-weighted brain imaging data from up to 225 adolescents (ages 14–17 years), 150 of whom are expected to have a current diagnosis of an anxiety and/or depressive disorder. Comprehensive clinical and neuropsychological evaluations and long-itudinal clinical data are also being collected. This article provides an overview of task functional magnetic resonance imaging (fMRI) protocols and preliminary findings (N = 140), as well as clinical and neuropsychological characterization of adolescents. Data collection is ongoing for an additional 85 adolescents, most of whom are expected to have a diagnosis of an anxiety and/or depressive disorder. Data from the first 140 adolescents are projected for public release through the National Institutes of Health Data Archive (NDA) with the timing of this manuscript. All other data will be made publicly-available through the NDA at regularly scheduled intervals. This article is intended to serve as an introduction to this project as well as a reference for those seeking to clinical, neurocognitive, and task fMRI data from this public resource